-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $79

Benzinga·02/18/2026 20:24:40
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $128 to $79.